# OnCo record rejuv-second-radiotherapy-dose-field-and-age (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/rejuv-second-radiotherapy-dose-field-and-age/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "rejuv-second-radiotherapy-dose-field-and-age" ;
  schema:name "Radiotherapy and second cancers: field, dose and age at exposure"@en ;
  schema:alternateName "Radiation-induced cancer"@en, "Second malignancy in the radiotherapy field"@en, "Out-of-field second cancer"@en ;
  schema:description "A radiation-induced cancer appears in or at the edge of the treated area, usually more than ten years later, and the risk rises with the dose the organ received and falls with the age at which the person was treated. Which organs sat in the field is therefore the question that decides everything that follows, and it is answerable from the radiotherapy record."@en ;
  schema:url <https://onco.cc/terms/rejuv-second-radiotherapy-dose-field-and-age/> ;
  schema:dateModified "2026-10-02"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Radiation-induced_cancer> ;
  schema:citation <https://doi.org/10.1016/S1470-2045(11)70061-4>, <https://doi.org/10.1016/j.radonc.2014.10.004>, <https://doi.org/10.1016/j.radonc.2016.08.017>, <https://doi.org/10.1136/bmj.i851>, <https://doi.org/10.1053/j.gastro.2004.12.038> ;
  onco:tag "rejuvenation", "survivorship", "second-cancers", "radiotherapy" ;
  onco:related <https://onco.cc/terms/rejuv-second-cancers-overview/>, <https://onco.cc/terms/second-primary-breast-after-chest-radiotherapy/>, <https://onco.cc/terms/second-primary-lung-after-chest-radiotherapy/>, <https://onco.cc/terms/second-primary-sarcoma-in-the-treated-field/>, <https://onco.cc/terms/second-primary-bowel-after-abdominal-radiotherapy/>, <https://onco.cc/terms/rejuv-second-choices-made-at-treatment/> ;
  onco:cancers <https://onco.cc/cancers/breast-cancer/>, <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/urothelial/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/lung-cancer/>, <https://onco.cc/cancers/sarcoma/> ;
  onco:sections <https://onco.cc/fronts/rejuvenation/>, <https://onco.cc/fronts/supportive-care/>, <https://onco.cc/fronts/prevention/> ;
  onco:technologies <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/brachytherapy/>, <https://onco.cc/terms/deep-inspiration-breath-hold/>, <https://onco.cc/technologies/survivorship-care-plan/> ;
  onco:terms <https://onco.cc/terms/second-cancers-after-radiotherapy/>, <https://onco.cc/terms/secondary-malignancy/>, <https://onco.cc/terms/late-effects/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-survivorship/>, <https://onco.cc/bottlenecks/b-surgery-radiation-innovation/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-schaapveld-second-cancer-risk-40-years-hodgkin-nejm-2015/> .